Virtu Financial LLC Makes New $266,000 Investment in Arvinas, Inc. (NASDAQ:ARVN)

Virtu Financial LLC purchased a new position in Arvinas, Inc. (NASDAQ:ARVN) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 6,474 shares of the company’s stock, valued at approximately $266,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Perceptive Advisors LLC acquired a new stake in shares of Arvinas during the fourth quarter worth about $14,574,000. Price T Rowe Associates Inc. MD lifted its holdings in shares of Arvinas by 42.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,832,123 shares of the company’s stock worth $157,731,000 after purchasing an additional 1,143,452 shares during the period. Opaleye Management Inc. acquired a new stake in shares of Arvinas during the fourth quarter worth about $10,854,000. Oracle Alpha Inc. acquired a new stake in shares of Arvinas during the fourth quarter worth about $490,000. Finally, Parkman Healthcare Partners LLC lifted its holdings in shares of Arvinas by 60.4% during the fourth quarter. Parkman Healthcare Partners LLC now owns 167,001 shares of the company’s stock worth $6,874,000 after purchasing an additional 62,884 shares during the period. Institutional investors and hedge funds own 95.19% of the company’s stock.

Arvinas Stock Performance

Shares of ARVN opened at $25.22 on Friday. Arvinas, Inc. has a one year low of $13.57 and a one year high of $53.08. The stock has a market capitalization of $1.73 billion, a price-to-earnings ratio of -4.25 and a beta of 1.98. The stock has a 50 day moving average price of $31.20 and a 200 day moving average price of $37.95.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.45. Arvinas had a negative return on equity of 64.79% and a negative net margin of 185.09%. The firm had revenue of $25.30 million during the quarter, compared to analysts’ expectations of $32.94 million. During the same period in the previous year, the business earned ($1.54) earnings per share. The firm’s revenue for the quarter was down 22.2% on a year-over-year basis. On average, analysts predict that Arvinas, Inc. will post -4.08 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have issued reports on ARVN shares. Truist Financial reissued a “buy” rating and issued a $65.00 price target on shares of Arvinas in a report on Monday, March 25th. Wells Fargo & Company decreased their price target on Arvinas from $63.00 to $60.00 and set an “overweight” rating for the company in a report on Thursday, May 9th. Barclays boosted their price target on Arvinas from $26.00 to $60.00 and gave the company an “overweight” rating in a report on Thursday, February 29th. Stifel Nicolaus decreased their price target on Arvinas from $72.00 to $68.00 and set a “buy” rating for the company in a report on Wednesday, May 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $87.00 price target on shares of Arvinas in a report on Friday, May 17th. Two investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $61.13.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.